Sign in
Not yet recruitingPhase 4

ARTENSIUM cream for knee osteoarthritis pain compared with placebo cream

Tests ARTENSIUM cream against placebo for pain in adults with knee osteoarthritis.

Key facts

Who runs it
Boiron
Where
France6 sites in 1 countryChoose a country to see its sites
Registry title
Study evaluating the effect of ARTENSIUM® cream on knee osteoarthritis pain.
Status
Not yet recruiting
Phase
Phase 4
People taking part
200 people, planned
Starts
4 Jan 2027
Expected to end
3 Jan 2028
Type of study
Interventional
Record updated
6 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 50 to 75 with knee osteoarthritis and mild to moderate knee pain that got worse over the last 15 days. It tests ARTENSIUM® cream against a placebo cream.

Age
50 to 75 years
Sex
Women and men
Disease stage
Knee osteoarthritis by American College of Rheumatology (ACR) criteria, with a knee X-ray in the previous 24 months. Mild to moderate knee pain (VAS ≥30 mm and ≤60 mm), rising over the previous 15 days. People must walk on their own, without wheelchair or walking frame.
Earlier treatment
No change in non-drug care, such as physiotherapy, in the 3 weeks before joining. No surgery, mesotherapy or joint injection in the study knee within 3 months. No ongoing opioids, nefopam, metamizole, corticosteroids, or aspirin at pain or anti-inflammatory doses. NSAIDs must be stopped at entry.
Biomarker or test result
CRP ≥3× the upper limit of normal, as a sign of acute infection or inflammation, means a person cannot join.

Main reasons for not taking part

  • Fluid in the knee joint, or knee pain coming from the back, hip or sacroiliac joint
  • Active cancer or ongoing cancer treatment
  • Full or partial artificial joint in the study knee
  • Chronic joint diseases such as rheumatoid arthritis, gout or chondrocalcinosis, or a knee injury in the last 6 weeks
  • Pregnant or breastfeeding, or allergy to the cream's ingredients such as chlorhexidine

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • Female or male patients aged from 50 to 75 years old
  • Diagnosis of knee osteoarthritis meeting the American College of Rheumatology (ACR) criteria, irrespective of the diagnostic modality used (clinical only, clinical-radiographic, or clinical-biological), with a knee radiograph performed within the previous 24 months
  • Mild to moderate knee pain (right or left knee) at inclusion (VAS ≥30 mm and ≤60 mm). In cases of bilateral knee involvement, the study knee (index knee) will be defined as the knee with the highest pain intensity at inclusion. In case of equal pain intensity, selection of the index knee will be left to the investigator’s discretion
  • Patient reporting a progressive increase in pain during the previous 15 days (pain greater than their usual stable condition)
  • No modification of non-pharmacological management (particularly physiotherapy) during the 3 weeks preceding inclusion. If physiotherapy is ongoing, treatment must have remained stable (same frequency and modalities) during the 3 weeks preceding inclusion
  • Patient has received and read the Information Sheet, has been given sufficient time to ask questions, and has voluntarily signed the informed consent form
  • Patient able to comply with scheduled visits, ambulate independently (without wheelchair or walking frame), correctly administer the investigational treatment independently or with assistance, and fulfil all other study requirements

Who cannot take part

  • Ongoing anticancer treatment, including hormonal therapies, targeted therapies, and immunotherapies, including adjuvant or maintenance treatment
  • History of surgery on the index knee within 3 months before inclusion
  • History of mesotherapy on the index knee within 3 months before inclusion
  • Intra-articular injection or infiltration in the index knee within 3 months before inclusion
  • Known hypersensitivity to any active substance or excipient of the investigational product (particularly chlorhexidine) or placebo. A test application on a small skin area will be performed at Day 0
  • Ongoing treatment with nefopam or metamizole, irrespective of formulation or indication
  • Ongoing corticosteroid therapy, regardless of route of administration
  • Referred pain originating from lumbar, sacroiliac, or hip disorders
  • Active cancer at inclusion
  • Acute inflammatory or infectious skin conditions: open wounds, eczema, skin rash
  • Any chronic or acute condition deemed by the investigator incompatible with study participation (e.g., neuropathic pain), or severe infection potentially compromising short-term prognosis
  • Suspected or confirmed acute infection or acute inflammatory disorder at inclusion, defined by suggestive clinical signs and/or CRP ≥3× the upper limit of normal
  • Any condition that, in the investigator’s opinion, would make participation unsuitable or prevent compliance with study requirements
  • Chronic rheumatologic disease, including : • chronic low back pain, chronic hip pain, • Autoimmune diseases involving the joints, including rheumatoid arthritis affecting the knee, systemic lupus erythematosus, psoriatic arthritis, and chronic inflammatory rheumatic disorders such as spondyloarthritis. • chronic osteomyelitis of the knee joint, • avascular necrosis of the femur or tibia, • lumbo-radiculopathy, • bone or cartilage neoplasms, • metabolic diseases such as gout or Paget’s disease. • Chronic inflammatory crystal arthropathy due to calcium pyrophosphate dihydrate (CPPD) crystal deposition disease (systemic chondrocalcinosis). Isolated asymptomatic meniscal calcification identified on radiographic imaging is not an exclusion criterion. In case of doubt, the presence of the term “chondrocalcinosis” in the patient's medical records should be considered exclusionary. • Tendinitis documented by imaging, periarticular bursitis, patellofemoral syndrome, iliotibial band syndrome, patellar or quadriceps tendinopathy
  • Ongoing opioid treatment at the time of inclusion, irrespective of formulation or indication
  • Knee joint effusion
  • Ongoing aspirin treatment at analgesic or anti-inflammatory doses. Low-dose aspirin used for antiplatelet purposes is permitted
  • Women of childbearing potential not using effective contraception, as well as pregnant or breastfeeding women
  • Individuals deprived of liberty or under legal protection measures in accordance with Articles L1121-6 and L1121-8 of the French Public Health Code
  • Patient not affiliated with or not benefiting from the French social security system
  • Participation in another clinical study at the time of inclusion
  • Ongoing systemic or topical NSAID treatment that cannot be discontinued at inclusion
  • Presence of a total or partial prosthesis on the index knee
  • Acute or subacute traumatic knee injuries (<6 weeks), including sprains, meniscal lesions, swelling, or fractures
  • Septic arthritis of the knee or monoarthritis of the knee

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the specific therapeutic effect of ARTENSIUM® cream compared with placebo on pain in patients with symptomatic knee osteoarthritis after 7 and 14 days of treatment.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An exploratory double-blind randomized placebo-controlled trial to evaluate the effect of ARTENSIUM® cream in the relief of pain in patients with knee osteoarthritis
Plain-language title
ARTENSIUM cream for knee osteoarthritis pain compared with placebo creamGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
6 October 2026